926 related articles for article (PubMed ID: 28583277)
1. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
2. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
3. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
4. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
[TBL] [Abstract][Full Text] [Related]
5. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?
Cheng G; Torigian DA; Zhuang H; Alavi A
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):779-87. PubMed ID: 23361859
[TBL] [Abstract][Full Text] [Related]
6. Limited diagnostic value of Dual-Time-Point (18)F-FDG PET/CT imaging for classifying solitary pulmonary nodules in granuloma-endemic regions both at visual and quantitative analyses.
Chen S; Li X; Chen M; Yin Y; Li N; Li Y
Eur J Radiol; 2016 Oct; 85(10):1744-1749. PubMed ID: 27666611
[TBL] [Abstract][Full Text] [Related]
7. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
8. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
[TBL] [Abstract][Full Text] [Related]
9. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
10. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.
Costantini DL; Vali R; Chan J; McQuattie S; Charron M
AJR Am J Roentgenol; 2013 Feb; 200(2):408-13. PubMed ID: 23345365
[TBL] [Abstract][Full Text] [Related]
11. Metabolic changes in breast cancer on dual-time-point
Kim HO; Kim BS; Kang SY; Bang JI; An J; Kim JH; Yoon HJ
Ann Nucl Med; 2020 Dec; 34(12):942-951. PubMed ID: 32974848
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease.
Cui J; Zhao P; Ren Z; Liu B
Medicine (Baltimore); 2015 Aug; 94(33):e1356. PubMed ID: 26287421
[TBL] [Abstract][Full Text] [Related]
13. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
14. Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?
Saleh Farghaly HR; Mohamed Sayed MH; Nasr HA; Abdelaziz Maklad AM
Indian J Nucl Med; 2015; 30(4):314-9. PubMed ID: 26430314
[TBL] [Abstract][Full Text] [Related]
15. The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.
Nakajo M; Nakajo M; Jinguji M; Fukukura Y; Nakabeppu Y; Tani A; Yoshiura T
Br J Radiol; 2015; 88(1055):20150552. PubMed ID: 26337605
[TBL] [Abstract][Full Text] [Related]
16. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
[TBL] [Abstract][Full Text] [Related]
18. The role of dual time point PET/CT for distinguishing malignant from benign focal 18F-FDG uptake duodenal lesions.
Sa R; Zhao HG; Dai YY; Guan F
Medicine (Baltimore); 2018 Sep; 97(38):e12521. PubMed ID: 30235771
[TBL] [Abstract][Full Text] [Related]
19. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
20. Using neighborhood gray tone difference matrix texture features on dual time point PET/CT images to differentiate malignant from benign FDG-avid solitary pulmonary nodules.
Chen S; Harmon S; Perk T; Li X; Chen M; Li Y; Jeraj R
Cancer Imaging; 2019 Aug; 19(1):56. PubMed ID: 31420006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
